# Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Source: https://onco.cc/trials/nct06901622/  
OnCo record `nct06901622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, nab-paclitaxel, S-1 and anlotinib in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.

## Summary

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma is a phase 2, randomised interventional study registered as NCT06901622 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 50 participants, started 2024-11-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1. Conditions listed: Gallbladder Cancer and Extrahepatic Cholangiocarcinoma. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06901622
- Phase: 2
- Setting: A Randomized Double-cohort Exploratory Clinical Study of Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06901622: https://clinicaltrials.gov/study/NCT06901622

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06901622.json